Parameswaran Hari, MD, MRCP

Chief, Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

Hindi, Urdu, Tamil, Malayalam, English

Secondary Appointments

Internal Medicine
Medical Oncology

Contact Information

(414) 805-6800

Education

MD - Doctor of Medicine
MRCP (U.K.) - Member Royal College of Physicians

Biography

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief in the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology in the United Kingdom and then in Medical Oncology and Transplantation at the Medical College of Wisconsin.

Research Interests

His primary clinical interests are in cellular therapies and plasma cell disorders - multiple Myeloma, Amyloidosis and other monoclonal gammopathies. Dr. Hari is also Scientific Director of the plasma cell disorders working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

(Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL.) Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15 PMID: 31526843 PMCID: PMC6942175 SCOPUS ID: 2-s2.0-85073734108 09/19/2019
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

(Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorror ML.) Bone Marrow Transplant. 2020 Jan;55(1):172-181 PMID: 31481800 PMCID: PMC6940535 SCOPUS ID: 2-s2.0-85072196038 09/05/2019
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.

(Hari P, Ung B, Abouzaid S, Agarwal A, Parikh K.) Future Oncol. 2019 Dec;15(35):4045-4056 PMID: 31625415 SCOPUS ID: 2-s2.0-85075795524 10/19/2019
An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.

(Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A.) J Clin Apher. 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.

(Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M.) Leuk Lymphoma. 2019 Nov 25:1-6 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019
Oprozomib in patients with newly diagnosed multiple myeloma.

(Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P.) Blood Cancer J. 2019 08 16;9(9):66 PMID: 31420532 PMCID: PMC6697695 SCOPUS ID: 2-s2.0-85071028408 08/20/2019
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.

(Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P.) Blood Cancer J. 2019 07 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

(Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756536 SCOPUS ID: 2-s2.0-85077165933 11/23/2019
Gut microbiome and CAR-T therapy

(Abid MB, Shah NN, Maatman TC, Hari PN.) Experimental Hematology and Oncology. 19 November 2019;8(1) SCOPUS ID: 2-s2.0-85075584597 11/19/2019
Oprozomib in patients with newly diagnosed multiple myeloma

(Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P.) Blood Cancer Journal. 1 September 2019;9(9) SCOPUS ID: 2-s2.0-85071028408 09/01/2019
Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

(Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Ali Hamidieh A, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitsky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D.) Hematol Oncol Stem Cell Ther. 2019 Aug 20 PMID: 31449781 08/27/2019
Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.

(Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J.) Hematol Oncol Stem Cell Ther. 2019 Aug 20 PMID: 31449780 SCOPUS ID: 2-s2.0-85071270497 08/27/2019